 On August 28, 2017, Gilead Sciences announced that it would acquire Kite Pharma for $11.9 billion in an all-cash deal, equating to $180 cash per share.The deal will add the promising CAR-T candidate to Gilead's existing portfolio.The acquisition was completed in October 2017.